Anakinra inhibits the NF-κB activity of CAFs by interrupting the tumor-matrix IL-1β-IRAK4 feedforward circuit, attenuating the pro-survival and chemoresistance effects of CAFs on PDAC cells. The gene discussed is NFKB1; the disease is neoplasm.